Wave Life Sciences announces hearing on proposed redomicilation

As previously announced, Wave Life Sciences (WVE) is seeking shareholders’ and Singapore High Court approvals in relation to a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore, in order to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States. Wave has made an application on April 16, 2026 to the Singapore High Court for approval to convene the meeting at which shareholder approval for the Scheme of Arrangement will be sought, as filed HC/OA 434/2026, which application will be heard before the Singapore High Court on April 29, 2026 at 1 Supreme Court Lane, Singapore 178879. The Singapore High Court has directed that any affidavits in response to the application must be submitted to the Singapore High Court by April 22, 2026, and that any written submissions or bundle of authorities must be filed with the Singapore High Court by April 24, 2026.